Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion guidelines have variable recommendations for maintaining fibrinogen levels in bleeding patients. An increasing number of studies support the practice of fibrinogen replacement therapy for acquired coagulopathies, and additional studies are underway. 
Introduction
Fibrinogen is a critical protein for clot formation, providing a matrix and mesh network essential for clot strength. Maintaining fibrinogen levels is an important therapeutic target in bleeding patients, particularly in perioperative settings. [1] [2] [3] Early studies demonstrated that fibrinogen repletion corrected clot strength, based on viscoelastic blood testing using thromboelastography/thromboelastometry. 4 Normal fibrinogen levels are elevated during pregnancy, 5 and cases studies indicate that fibrinogen repletion may be effective in the treatment of postpartum hemorrhage. 6, 7 Additionally, studies have been published, or are underway, that provide supporting evidence for the role of fibrinogen repletion for treating acquired coagulopathy. 1, [8] [9] [10] Although precise levels for fibrinogen repletion remain to be defined as a therapeutic trigger or target, we review the current evidence and provide therapeutic perspectives in clinical settings.
The role of fibrinogen and related proteins in clot formation
A 62-year-old 110 kg man underwent first time cardiac surgery with a valve sparing aortic root replacement. Preoperative medications included a statin and beta blocker.
Intraoperatively, 52,000 units of heparin were administered and reversed with 250 mg of protamine. He was empirically transfused plasma (4 units) and pheresed platelets (2 units) for bleeding. In the ICU he was warm, hemodynamically stable but bleeding ~150 mL/hour. Coagulation tests obtained on ICU arrival included ACT-120 secs, platelet count-115,000, INR-1.3, PTT-37 secs, and fibrinogen of 120 mg/dL.
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Question: What therapy should be considered to treat the bleeding?
Fibrinogen is a hepatically synthesized 340 kDa plasma glycoprotein that is the substrate for thrombin, plasmin, and Factor XIIIa (FXIIIa), with a half-life of 3-5 days. 11 Following tissue injury, fibrinogen is cleaved by thrombin and generates soluble fibrin monomers that create a net that entraps red blood cells (RBCs) to form a clot. The fibrin polymers are cross linked by FXIIIa, improving clot strength and preventing fibrinolysis.
Fibrinogen also binds to platelet glycoprotein IIb/IIIa receptors to promote platelet aggregation, further facilitating cross linking and clot stabilization. Thus, fibrinogen is a critical component and substrate for clot formation, amplification, and strength.
Fibrinogen circulates at the highest concentration of the plasma coagulation factors. Following substantial blood loss and hemorrhage, hypofibrinogenemia occurs due to hemodilution from volume replacement, and consumption by clot formation or as a result of disseminated intravascular coagulation (DIC). [12] [13] [14] Thus, fibrinogen supplementation to restore plasma levels is an important component for normalizing clot formation in bleeding patients. Other coagulation factor levels are also diminished, resulting in complex coagulopathies in patients with substantial hemorrhage following surgery, trauma, and/or extracorporeal circulation. Factor XIII (FXIII) deficiency due to dilutional changes or consumption may also develop, contributing to bleeding perioperatively. [15] [16] [17] Studies using thromboelastography to measure clot strength in FXIIIdeficient plasma have demonstrated that changes in FXIII activity significantly increase clot strength. 18 Therapeutic considerations in coagulopathic bleeding patients should therefore be multimodal, including not only fibrinogen replacement therapy but also However, studies report fibrinogen supplementation in surgical patients at higher levels. 1, 34, 40, 41 More recent European trauma guidelines from 2013 recommend fibrinogen administration at levels <1.5-2.0 g/L. 20 In other settings, such as pregnancy, different therapeutic thresholds may need to be considered. In peripartum patients, fibrinogen levels increase to 500-600 mg/dL (5-6 g/L), and levels <2.0 g/L are considered to be highly predictive for risk of postpartum hemorrhage (PPH).
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Measuring fibrinogen levels 
Plasma
Plasma is transfused extensively in trauma and surgical patients. 46 However, recent systematic reviews suggest there is no benefit for most clinical indications, except in trauma, [46] [47] [48] [49] while some studies report increased morbidity associated with its use. 50, 51 Different plasma preparations are available and used including single-donor fresh frozen plasma (FFP), plasma frozen within 24 hours of collection (FP24) and thawed plasma (used within 5 days of initial thaw), but these products are not ideal sources for repletion, as fibrinogen concentrations can vary from 1-3 g/L. 30 Transfusing plasma for fibrinogen repletion also requires large volumes that may be helpful for patients with trauma- mL/kg increases plasma fibrinogen levels only 0.4 g/L, whereas 33.5 mL/kg increases levels by 1.0 g/L. 52 Despite this information, clinicians continue to use plasma therapy for fibrinogen supplementation. A recent analysis evaluated the evidence for plasma use compared to fibrinogen concentrates from studies reporting bleeding, transfusion requirements, and fibrinogen levels in patients given plasma or fibrinogen concentrates in trauma or surgical settings. 53 The authors found 70 plasma and 21 fibrinogen concentrate studies, mostly derived from observational data. The benefits or efficacy of plasma were inconsistent, with improved outcomes in 28% of the studies compared to worse outcomes in 22% of the studies. The authors noted a reduction of mortality in 50% of the massive bleeding or trauma patient studies, and increased mortality in 20% of non-massive bleeding and surgical patients. The fibrinogen concentrate data included only 5 studies where fibrinogen concentrate was assessed versus a comparator, of which 70% had improved outcomes. Overall, the risk of transfusion-associated circulatory overload (TACO) and inability to replete fibrinogen levels precludes plasma as an effective therapy. Fibrinogen concentrates or cryoprecipitate are more effective at fibrinogen repletion.
34,41
Cryoprecipitate Cryoprecipitate, discovered by Judith Graham Pool, was used for treating patients with hemophilia A before the availability of lyophilized clotting factor concentrates. 54 Cryoprecipitate is obtained by thawing FFP at 1-6˚C, centrifugation, and resuspending
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From the precipitated proteins in plasma and refreezing. 55 Cryoprecipitate also contains fibrinogen, von Willebrand factor, and FXIII, and is used extensively as a fibrinogen source. Each unit of cryoprecipitate contains ~200-250 mg of fibrinogen and a standard dose is 8-10 units for adults, although fibrinogen concentration can vary among units. 56 Cryoprecipitate repletes fibrinogen, but is also used for deficiencies in von Willebrand factor and FXIII.
Because cryoprecipitate therapy is a multi-donor product with no anti-viral processing, it is not available in some countries due to safety concerns. 57 However, alternatives to cryoprecipitate may not be available in all countries. Cryoprecipitate needs to be inventoried according to blood group compatibility, and requires time for thawing and pooling before transfusion. Although widely used, studies and/or evidence for its use are limited. 58 Guidelines suggest that cryoprecipitate should not be used to control bleeding related to low fibrinogen levels if specific factor concentrates are available.
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Fibrinogen concentrates
Commercial fibrinogen concentrates are available as pasteurized, lyophilized products from pooled donors that undergo purification, viral inactivation, and removal processes and don't require cross matching. Normal MCF values are 9-25 mm that correlate with normal fibrinogen levels; 65 however, a target MCF of 22 mm has been used in aortic surgery patients (achieved using mean fibrinogen doses of 5.7 g). 40 In the algorithm by Weber, 25 mg/kg fibrinogen concentrate is recommended if EXTEM A10 and FIBTEM A10 are below 40 mm and 8 mm, respectively. 66 If FIBTEM A10 is <6 mm and EXTEM A10 is <40 mm, the recommended dose increases to 50 mg/kg. 66 Dosing strategies are reviewed in Table 1 .
Of interest is a publication by Collins, who developed a model that evaluates increasing fibrinogen levels by either plasma, cryoprecipitate, or fibrinogen concentrate. 67 There is a perceived risk of triggering a thromboembolic event associated with fibrinogen supplementation, and that administering excessive fibrinogen, particularly with high thrombin generation, may increase the risk of systemic microthrombogenicity.
However, post-hoc analysis of a randomized clinical trial of fibrinogen concentrate reported fibrinogen supplementation was not associated with significant alterations of hemostatic parameters. 68 In a porcine model there were no reports of hypercoagulability or thromboembolism following treatment with fibrinogen levels up to 600 mg/kg. Fibrinogen repletion, primarily with the use of fibrinogen concentrates for acquired bleeding, has been reported in clinical settings including surgery, trauma, and obstetrics (reviewed by Levy et al. 30 ).
Trauma
Fibrinogen levels are decreased in trauma patients on admission, and are associated with poor outcomes. 69 Fibrinogen repletion is increasingly used as hemostatic treatment for trauma-induced coagulopathy, especially with concentrates. 62, 70 However, hypovolemic patients are initially resuscitated with plasma following a massive
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Fibrinogen and other factor concentrates are increasingly being studied and reported in surgical and trauma algorithms as a management protocol for treating hemorrhage. Goal-directed coagulation management using fibrinogen concentrates and prothrombin complex concentrates (PCC) improved survival rates as compared with those predicted by the Trauma Injury Severity Score (TRISS) in a retrospective report of 131 patients. 63 Another retrospective report included 601 patients receiving FFP without factor concentrates, and noted greater transfusion requirements with RBCs or platelet concentrates compared with 80 trauma patients who received fibrinogen concentrate and/or PCC. 71 A prospective evaluation of 144 patients with major blunt trauma also reported coagulation factor concentrates corrected coagulopathy, and reduced RBC and platelet transfusion compared with those receiving FFP, and fewer patients developed multi-organ failure. 72 However, overall mortality was not reduced with fibrinogen concentrates in another retrospective study of 294 trauma patients. 73 Current European guidelines for managing bleeding in trauma patients with fibrinogen levels <1.5-2.0 g/L recommend an initial fibrinogen concentrate dose of 3-4 g, with further dosing guided by laboratory testing. 20 There are additional studies underway, including prospective management protocols (Schöchl et al. 74 ), and two ongoing
European trials of fibrinogen concentrates in trauma. However, multimodal approaches are important to consider, including the use of antifibrinolytic agents. 
Cardiovascular surgery
Cardiovascular surgical patients bleed due to multiple coagulation defects associated with cardiopulmonary bypass, tissue injury, and dilutional changes. 75 Multiple risk factors significantly influence bleeding including reoperation, type of surgical procedure (aortic root replacement, multiple valve replacements), cardiopulmonary bypass time, renal dysfunction, and factors unique to this patient population. 76 Additionally, cardiac surgery patients have hemostatic changes consistent with DIC, including elevated D-dimers, low fibrinogen, increased PT and PTT, thrombocytopenia, and low antithrombin levels. However, preoperative fibrinogen levels are reported to be an independent predictor of postoperative bleeding and transfusion requirement after coronary artery bypass grafting (CABG) surgery. 77 Preoperative fibrinogen concentrations <3 g/L are reported to increase perioperative blood loss and transfusion requirements after CABG. 77 In a prospective, observational study of 1,956 patients undergoing cardiac surgery, fibrinogen levels on ICU admission were lower in bleeding patients (2.5 ± 0.8 g/L and 2.1 ± 0.8 g/L in the control and excessive bleeding groups, respectively), and were a predictor of bleeding. 78 Studies also suggest fibrinogen repletion will reduce bleeding and the need for allogeneic blood products. 79 A prospective study of fibrinogen concentrates in 61 patients with bleeding post-cardiopulmonary bypass (CPB) noted fibrinogen reduced transfusions compared to placebo (2 U versus 13 U, respectively), and transfusion avoidance was achieved in half of the patients. 1 Other prospective and retrospective cardiac surgical studies, including high risk ascending aortic replacement 
severe PPH, and, the risk was 2.63-fold higher for each 1 g/L decrease. 25 The negative predictive value of fibrinogen >4 g/L was 79% and the positive predictive value of <2 g/L was 100%. A case control study including three groups of women after a first pregnancy (severe PPH, non-severe PPH, and asymptomatic controls; 317 in each group) observed that fibrinogen levels <2 g/L were independently associated with a significant risk of severe PPH. 26 An additional report evaluating the specificity of fibrinogen levels <2 g/L for predicting severe PPH was ~99% and the odds ratio was ~12. 84 A prospective analysis for the need for embolization or surgical interventions for severe PPH on ICU admission reported that a fibrinogen level <2 g/L was an independent predicator. 85 Additional analysis of 456 patients with PPH >1500 mL reported fibrinogen levels correlated with blood loss. 86 Further studies in PPH report that fibrinogen concentrate therapy is important in patients with hypofibrinogenemia. 6 Initial fibrinogen levels below 2 g/L in women with PPH are associated with more severe hemorrhage. In these emergency settings, fibrinogen concentrate allows rapid therapy without blood type matching; however, there are limited data and no published randomized clinical trials in this setting. The FIB-PPH trial investigated if early fibrinogen concentrate treatment reduced transfusions in PPH. 87 This randomized, placebo-controlled, double-blind trial included patients after vaginal delivery with acute blood losses, as follows: 
Orthopedic surgery
Orthopedic surgery is associated with blood loss and risk of dilutional coagulopathy and impaired fibrin polymerization. 88 In a prospective study of 66 patients, repletion with fibrinogen concentrate maintained clot firmness. 89 In another study of children undergoing surgical craniosynostosis repair, repeated fibrinogen doses restored hemostasis without additional need for transfusions. 90 In a similar study, using a ROTEM-assisted algorithm, factor concentrates reduced intraoperative transfusion requirements.
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Summary
Fibrinogen is a critical hemostatic protein required for both prevention and treatment of bleeding. Fibrinogen levels can best be repleted with either cryoprecipitate (containing fibrinogen, factor VIII, von Willebrand factor, and FXIII) or a commercial fibrinogen concentrate. An increasing number of studies have examined the role of fibrinogen as a therapeutic target, for its use in acquired coagulopathies. Therapy in the bleeding patient should be multimodal to include repletion of other coagulation proteins.
Fibrinogen concentrate represents an important option for treating coagulopathic
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From bleeding, allowing reduction of allogeneic blood product transfusion. Further multicenter studies in a variety of clinical settings are needed to determine optimal dosing strategies and target thresholds for fibrinogen therapy. An algorithm with suggested management strategies for the bleeding patient with a focus on fibrinogen measurement and repletion strategies is included in Figure 1 . 
